Article
Endocrinology & Metabolism
Zora Messner, David Carro-Vazquez, Judith Haschka, Johannes Grillari, Heinrich Resch, Christian Muschitz, Peter Pietschmann, Jochen Zwerina, Matthias Hackl, Roland Kocijan
Summary: This study investigated circulating miRNAs as potential biomarkers for monitoring treatment response in women with postmenopausal osteoporosis on denosumab therapy. The results showed significant changes in expression of seven miRNAs after two years of treatment, which correlated with changes in bone mineral density and bone turnover markers.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Karine Briot, Anne-Marie Schott, Jean-Philippe Sanchez, Jean-Vannak Chauny, Pascale Samama, Gaelle Desamericq
Summary: In a real-world clinical practice in France, postmenopausal women with osteoporosis showed high persistence with denosumab at 12 and 24 months, with a good tolerability profile.
Article
Orthopedics
Jiemei Gu, Hao Zhang, Qingyun Xue, Li Wang, Zhifeng Cheng, Yawei Zhang, Qifu Li, Lingqing Yuan, Yukun Li, Jin Dong, Yanan Huo, Xin Tang, Ling Hu, Xinjia Wang, Fei Hua, Lin Shen, Jinluo Cheng, Huimin Zhou, Youjia Xu, Tao Yang, Chuansuo Wang, Jin Xu, Jie Shen, Ying Zhang, Xiaomei Zhang, Dun Hong, Xiaoling Guan, Xinhua Xiao, Guang Wang, Yonghua Liu, Liujun Fu, Jianting Chen, Xigao Cheng, Yue Ding, Lijun Liu, Qi Yao, Xinchao Zhang, Lixin Li, Panjun Zhang, Chunying Deng, Chengyan Jiang, Li You, Kai Wang, Shimin Zhang, Jianzhong Xiao, Wei Liu, Xiaohong Du, Xianwen Shang, Tianrong Pan, Chen Lei, Shuren Guo, Zhenlin Zhang
Summary: This study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of a denosumab biosimilar (LY06006) in Chinese postmenopausal women with osteoporosis. The results showed that LY06006 significantly increased bone mineral density and reduced bone resorption. The safety and tolerability of LY06006 were comparable to the reference drug Prolia(R).
JOURNAL OF ORTHOPAEDIC TRANSLATION
(2023)
Article
Medicine, General & Internal
Taewook Kang, Si Young Park, Soon Hyuck Lee, Jong Hoon Park, Seung Woo Suh
Summary: This study compared the effects of DEN and ZOL on postmenopausal women with osteoporosis and found that DEN was associated with greater increase in BMD and TBS, as well as greater inhibition of bone remodeling compared with ZOL.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Endocrinology & Metabolism
Delphine Farlay, Sebastien Rizzo, David W. Dempster, Shuang Huang, Arkadi Chines, Jacques P. Brown, Georges Boivin
Summary: In postmenopausal women with osteoporosis, denosumab therapy for 10 years significantly increased bone mineralization, with more pronounced changes within the first 5 years. The study showed that denosumab treatment for 5 years led to a transition of mineral to more mature crystals and lower microhardness, indicating a persistence of low bone remodeling state at 5 and 10 years.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Ruxu You, Jinyu Liu, Lei Ke, Min Wan, Yu Zhang, Guangyi Yu, Takahiro Mori
Summary: This study found that sequential denosumab/zoledronic acid is cost-effective compared to zoledronic acid monotherapy for Chinese postmenopausal osteoporotic women over 70 years old.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Yi Chen, Jun Zhu, Yiqin Zhou, Jinhui Peng, Bo Wang
Summary: Denosumab is a promising antiresorptive agent in postmenopausal women with osteoporosis or low bone mineral density, showing greater increase in bone mineral density and reduced fracture risk compared to placebo, without excess risks of adverse events.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Endocrinology & Metabolism
Tomaz Kocjan, Antonela Sabati Rajic, Andrej Janez, Gaj Vidmar, Nina Orehek, Janja Marc, Barbara Ostanek
Summary: This retrospective study compared bone mineral density changes in postmenopausal women with severe osteoporosis after stopping teriparatide therapy and receiving denosumab or bisphosphonates treatment for 12 months. The results showed that after 12 months, sequential denosumab treatment appeared to yield higher additional lumbar spine bone mineral density gain compared with bisphosphonates treatment.
ENDOCRINE PRACTICE
(2021)
Review
Pharmacology & Pharmacy
Yang Sun, Yue Li, Jiangbi Li, Xiaoping Xie, Feng Gu, Zhenjiang Sui, Ke Zhang, Tiecheng Yu
Summary: The study found that a combination treatment of teriparatide and denosumab in postmenopausal osteoporosis patients leads to greater increase in bone density compared to monotherapy, without significant difference in adverse events.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Cristiana Cipriani, Sara Piemonte, Luciano Colangelo, Viviana De Martino, Daniele Diacinti, Federica Ferrone, Valentina Piazzolla, Valeria Fassino, Luciano Nieddu, Salvatore Minisola, Jessica Pepe
Summary: The study evaluated the early effect of denosumab on circulating markers of atherosclerosis in postmenopausal women with osteoporosis. It was found that 24 months of treatment with denosumab did not have an effect on these markers. Fluctuations in ICAM-1, CD40L, MMPs, FBG, and hs-CRP in serum were attributed to the immunological mechanisms stimulated by denosumab and zoledronic acid.
Review
Medicine, General & Internal
Jose Luis Alonso Perez, Sebastian Martin Perez, Andrea Battaglino, Jorge H. Villafane, Alexandra Alonso-Sal, Eleuterio A. Sanchez Romero
Summary: This systematic review indicates that muscle strengthening exercise is beneficial for postmenopausal women with osteoporosis, showing positive effects in improving bone density, muscle strength, balance, functionality, and quality of life.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Anna Wawrzyniak, Marzena Skrzypczak-Zielinska, Michal Michalak, Marta Kaczmarek-Rys, Alicja Ewa Ratajczak, Anna Maria Rychter, Kinga Skoracka, Michalina Marcinkowska, Ryszard Slomski, Agnieszka Dobrowolska, Iwona Krela-Kazmierczak
Summary: This study aimed to determine the influence of VDR gene variation on anti-osteoporotic one-year treatment with denosumab in Polish women with postmenopausal osteoporosis. The results showed that BB and Bb genotypes of the Bsml polymorphism of the VDR gene determine higher DXA parameter values both before and after one-year denosumab therapy in postmenopausal women with osteoporosis.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Orthopedics
Filippo Migliorini, Nicola Maffulli, Giorgia Colarossi, Joerg Eschweiler, Markus Tingart, Marcel Betsch
Summary: This study found that Denosumab has a higher impact on spine bone mineral density in selected postmenopausal women, and has the highest influence on hip and femur bone mineral density.
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH
(2021)
Article
Endocrinology & Metabolism
Namki Hong, Sungjae Shin, Seunghyun Lee, Kyoung Jin Kim, Yumie Rhee
Summary: This study investigated the effect of raloxifene use after DMab treatment on bone loss. The results showed that raloxifene could attenuate lumbar spine bone density loss in postmenopausal women after discontinuation of DMab treatment.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Article
Medicine, General & Internal
Chaiho Jeong, Jinyoung Kim, Jeongmin Lee, Yejee Lim, Dong-Jun Lim, Ki-Hyun Baek, Jeonghoon Ha
Summary: This study retrospectively evaluated the effectiveness of denosumab treatment in 189 postmenopausal osteoporosis patients. The results showed that calcium supplementation had no significant effect on bone density, bone marker changes, or hypocalcemia incidence during denosumab treatment under regular dietary intake.
JOURNAL OF CLINICAL MEDICINE
(2023)